The global next generation sequencing market is increasingly shaped by how vendors combine hardware, consumables, and analytics into complete offerings. Valued at USD 11.74 billion in 2025, the market is projected to reach USD 13.14 billion in 2026 and USD 34.47 billion by 2034, growing at a CAGR of 12.8% during the forecast period 2026–2034. Key players include Illumina Inc., Thermo Fisher Scientific Inc., Roche Ltd., Qiagen, Oxford Nanopore Technologies, BGI, Bio-Rad Laboratories, Inc., Perkin Elmer, Inc., Eurofins GATC Biotech GmbH, Invitae Corporation, PierianDx, DNASTAR, Inc., and Genomatix GmbH.

Sequencing Instruments Lead Product Demand

The product landscape spans instruments, reagents and consumables, and services. Sequencing instruments accounted for the largest share in 2025 at an estimated 38.21%, supported by strong demand for advanced equipment in clinical diagnosis and treatment. Rising demand for high-throughput, automated systems in clinical diagnostics sustains this dominance, while technological advances enable faster and more efficient DNA and RNA sequencing. For laboratories, sequencing instruments provide the reliable genetic information on which clinical diagnosis and illness treatment depend.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/next-generation-sequencing-ngs-market

Bioinformatics Services Drive Service Segment Growth

The services segment is anticipated to grow fastest during the forecast period. As demand for data analysis and interpretation rises, these offerings are becoming more crucial for understanding complex genetic information. Cloud-based computing allows researchers and healthcare professionals to access and analyze vast genetic datasets, and a rising preference for genomic testing services adds momentum. Healthcare institutions increasingly outsource analysis, interpretation, and bioinformatics services to specialized providers. AI-based bioinformatics services and platforms also reduce manual intervention, increase sequencing accuracy, and lower operational costs. Growth in cloud-based analysis and AI-enabled interpretation contributes to high-value B2B software revenues.

NGS Data Analysis and Workflow Segmentation

Workflow segmentation covers pre-sequencing (nucleic acid extraction and library preparation), sequencing, and post-sequencing data analysis. The sequencing segment led in 2025 and is expected to register the fastest growth during the forecast period. The post-sequencing segment is also projected to witness significant growth. NGS data analysis software platforms are increasingly used for clinical diagnosis because of reduced installation costs, and the easy availability of proteomic and genomic data creates further opportunities. Analysis is organized into primary, secondary, tertiary, and bioinformatics layers. Wider use of NGS data analysis is tempered by high sequencing technology costs and data management challenges, which restrain market expansion.

Whole Exome Sequencing and RNA Sequencing in the Technology Mix

The technology outlook spans whole genome, targeted, chip, de novo, and methyl sequencing alongside whole exome sequencing and RNA sequencing. Whole exome sequencing covers only protein-coding regions, delivering high depth for coding regions at moderate cost, medium data volume, and moderate turnaround. It is used for genetic disorder diagnosis and rare disease identification, though it misses mutations in non-coding regions.

Regional and Regulatory Landscape

North America led the next generation sequencing market in 2025 with an estimated 44.66% share, while Asia Pacific is expected to record the highest growth, a CAGR of 16.76%. Regulation shapes market entry. In the U.S., the FDA regulates NGS-based in vitro diagnostics, requiring analytical and clinical validation through 510(k), PMA, or De Novo pathways. The EU IVDR 2017/746 introduces risk-based classification, notified body assessment, clinical evidence, and post-market surveillance. In Asia-Pacific, China's NMPA may require local clinical data, while Japan's PMDA often aligns with global standards but demands additional validation. ISO standards such as ISO 15189 support consistent quality and data integrity.

Competitive Strategies and Outlook

Leading players invest heavily in research and development to expand product lines, pursuing product launches, agreements, mergers and acquisitions, and collaborations. Manufacturing locally to minimize operational costs is another key tactic. In July 2025, QIAGEN expanded its NGS portfolio with QIAseq xHYB Long Read Panels, which support platforms such as PacBio for structural variants, repeat expansions, and HLA typing. With sequencing costs continuing to fall and turnaround times improving, the next generation sequencing market is set to become more accessible across clinical diagnostics, research, and drug discovery.

More Trending Latest Reports By Polaris Market Research:

top-5-companies-transforming-electric-vehicle-ev-parts-and-components-market-in-2025

bearings-market

understanding-the-role-of-ignition-coils-in-modern-automotive-combustion

brain-machine-interface-market

natural-stone-market

customer-experience-management-market

artificial-intelligence-in-manufacturing-market

types-of-market-research

loitering-munition-market